SCHEMBL321868

SCHEMBL321868

O=C1NCC[C@H]1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL121281 1.00
SCHEMBL121282 1.00
Hydrochloric Acid SCHEMBL18270772 0.97
SCHEMBL1105059 0.84
SCHEMBL1105058 0.84
SCHEMBL2785455 0.84
SCHEMBL12611124 0.82
SCHEMBL29101472 0.76
SCHEMBL27426780 0.74
SCHEMBL14830432 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094678-A AP 2-related kinase 1 inhibitors and uses thereof 2026-05-26 CN disclosed
CN-117024411-B Isoquinoline as HPK1 inhibitor 豪夫迈·罗氏有限公司 2026-05-19 CN disclosed
EP-4638446-A1 THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2025-10-29 EP disclosed
EP-4396183-B1 SUBSTITUTED S-ALANINATE DERIVATIVES BAYER AG (DE) 2025-09-03 EP disclosed
US-20250270222-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF SATELLOS BIOSCIENCE INC. (CA) 2025-08-28 US disclosed
WO-2025136811-A1 CHEMICAL COMPOUNDS AND USES THEREOF IDEAYA BIOSCIENCES, INC. (US) 2025-06-26 WO disclosed
US-20250122207-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF SATELLOS BIOSCIENCE INC. (CA) 2025-04-17 US disclosed
WO-2025054448-A1 AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF SATELLOS BIOSCIENCE INC. (CA) 2025-03-13 WO disclosed
US-20250074881-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2025-03-06 US disclosed
US-20250002483-A1 SUBSTITUTED S-ALANINATE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2025-01-02 US disclosed
EP-0958290-A1 1,4-DIHYDROPYRIDIN DERIVATIVES AND THEIR USE IN THERAPY LABORATOIRE L. LAFON (FR) 1999-11-24 EP disclosed
WO-1998031680-A1 1,4-DIHYDROPYRIDIN DERIVATIVES AND THEIR USE IN THERAPY LABORATOIRE L. LAFON (FR) 1998-07-23 WO disclosed
US-4794186-A CEPHALOSPORINS INTERMEDIATES TANABE SEIYAKU CO., LTD. (JP) 1988-12-27 US disclosed
EP-0147181-A2 Thiazolylacetic acid derivatives and their preparation Tanabe Seiyaku Co., Ltd. (JP) 1985-07-03 EP disclosed
EP-0057846-B1 PYRROLIDINE DERIVATIVE, PROCESS AND INTERMEDIATES FOR ITS PREPARATION AND MEDICAMENTS CONTAINING IT F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1985-06-05 EP disclosed
US-4461906-A IMPROVING INTELLECTUAL CAPACITY HOFFMANN-LA ROCHE INC. (US) 1984-07-24 US disclosed
US-4452807-A CENTRAL NERVOUS SYSTEM DISORDERS HOFFMANN-LA ROCHE INC. (US) 1984-06-05 US disclosed
EP-0024030-B1 PYRROLIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1983-03-30 EP disclosed
EP-0057846-A1 Pyrrolidine derivative, process and intermediates for its preparation and medicaments containing it F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1982-08-18 EP disclosed
EP-0024030-A1 Pyrrolidine derivatives, processes for their preparation and pharmaceutical compositions containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-02-18 EP disclosed